Metropolis Healthcare Ltd will issue bonus shares in a 3:1 ratio on a record date of 20 March 2026, meaning shareholders will get 3 new shares for every 1 share held, with bonus equity credited on or before 23 March–3 April 2026, funded entirely from free reserves without any cash outflow.

Metropolis Healthcare 3:1 Bonus Issue – Key Facts

• Bonus ratio: 3:1 – three (3) new fully paid-up equity shares of face value ₹2 for every one (1) existing fully paid-up equity share of face value ₹2.

• Record date: Friday, 20 March 2026 – only shareholders on this date are eligible for bonus shares.
• Deemed date of allotment: Monday, 23 March 2026 (per SEBI circular); credit/dispatch expected on or before 3 April 2026.
• Pre‑bonus capital: 5,18,31,942 shares (₹2 FV) – paid-up capital ₹10.36 crore.​
• Post‑bonus capital: 20,73,27,768 shares (₹2 FV) – paid-up capital ₹41.46 crore, authorized capital unchanged at ₹63.86 crore.​
• Total bonus shares: 15,54,95,826 equity shares of face value ₹2 each; reserve utilization ~₹31.09 crore.​
• Source of funds: Securities Premium, General Reserve, Retained Earnings from audited FY25 accounts – no cash consideration to shareholders.​
• Q3 FY26 performance: Revenue ₹406 crore (+25.8% YoY), PAT ₹42 crore (+33.7% YoY), EBITDA ₹95 crore (+32.4% YoY), margin improved to 23.4%.

Illustration: If the stock is at ₹1,800 pre‑bonus and you hold 10 shares, after 3:1 bonus you will hold 40 shares and the price will theoretically adjust to around ₹450 – total value stays ~₹18,000 (ignoring market moves).

What 3:1 Bonus Means for Metropolis Shareholders

• Share count multiplies by 4: 3 extra shares for each existing share → holding becomes 4x in number, though total economic value remains same at the time of adjustment.​

• Price adjustment: Market price generally adjusts to ~¼ of pre‑bonus price on ex‑bonus date, but actual level depends on demand-supply and sentiment.​
• Liquidity boost: More free‑float shares often mean tighter spreads and higher trading volumes, making entry/exit easier for investors.
• No change in market cap: Bonus shares come from reserves; company valuation doesn’t change just because of the split of units.
• Signal of confidence: Management is using strong reserves (Securities Premium ₹24,926.52 lakh, General Reserve ₹2,987.38 lakh, Retained Earnings ₹94,702.25 lakh) to reward shareholders, indicating healthy balance sheet and growth visibility.

Strengths of Metropolis Healthcare Bonus Issue

• Strong reserves & net-debt-free status support the ₹31.09 crore reserve transfer without stressing the balance sheet.
• Q3 FY26 performance robust with 26%+ revenue growth and 52% PAT growth (ex‑exceptional); bonus aligns with earnings momentum.
• Improved EBITDA margin to ~23–25% shows operating leverage in diagnostics, backing management’s confidence to issue bonus shares.
• 3:1 bonus makes the stock more affordable on a per‑share basis post adjustment, aiding retail participation and liquidity.
• All bonus shares rank pari passu with existing shares for dividends and voting, ensuring no class differentiation for new units.​

Risks & Considerations Around the 3:1 Bonus

• No intrinsic value creation – bonus is cosmetic; business fundamentals and growth still drive long‑term returns, not the corporate action itself.
• EPS and per‑share ratios dilute mechanically as share count quadruples, so valuation multiples (P/E, EPS) must be re‑interpreted post bonus.
• Short‑term volatility likely around ex‑bonus and record date as traders rotate for bonus capture and profit‑booking..
• Higher free-float can increase speculation, making the stock more sensitive to news and quarterly results.​
• If growth slows after bonus, expanded equity base may cap per‑share earnings growth and pressure valuations, especially at rich multiples.